BioAlliance Pharma: Presentation of Phase I Clinical Results With AMEP® Biotherapy in the Treatment of Metastatic Melanoma

Published: Oct 01, 2012

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, presented safety and tolerance results of the phase I clinical study with the AMEP® biotherapy in the metastatic melanoma at the annual congress of ESMO (European Society for Medical Oncology) in Vienna, Austria (September 28th – October 1st).

Back to news